Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-120604
Filing Date
2018-04-18
Accepted
2018-04-18 12:01:33
Documents
15
Period of Report
2018-05-31
Effectiveness Date
2018-04-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A d521080ddef14a.htm DEF 14A 333032
2 GRAPHIC g521080bottom.jpg GRAPHIC 4974
3 GRAPHIC g521080dsp003aa.jpg GRAPHIC 10614
4 GRAPHIC g521080dsp01.jpg GRAPHIC 18101
5 GRAPHIC g521080dsp01a.jpg GRAPHIC 16159
6 GRAPHIC g521080dsp01b.jpg GRAPHIC 9732
7 GRAPHIC g521080dsp01c.jpg GRAPHIC 3232
8 GRAPHIC g521080dsp01d.jpg GRAPHIC 16434
9 GRAPHIC g521080dsp02.jpg GRAPHIC 3845
10 GRAPHIC g521080dsp03.jpg GRAPHIC 4049
11 GRAPHIC g521080dsp03b.jpg GRAPHIC 2728
12 GRAPHIC g521080dsp03c.jpg GRAPHIC 4603
13 GRAPHIC g521080g49g15.jpg GRAPHIC 9233
14 GRAPHIC g521080page_040.jpg GRAPHIC 27994
15 GRAPHIC g521080snap1.jpg GRAPHIC 2735
  Complete submission text file 0001193125-18-120604.txt   521162
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-22873 | Film No.: 18760614
SIC: 2835 In Vitro & In Vivo Diagnostic Substances